2nd Annual Global Business Intelligence Summit

eyeforpharmaMarch 18-19, 2009, Nassau Inn, Princeton, New Jersey, USA.
Pharma & Biotech companies seeking competitive advantage are now relying on BI as an innovation and decision-making driver. Innovative strategies offer the possibility of transforming insight into action, of making decisions quickly, and capitalizing on opportunities more fully.

eyeforpharma's 2nd Annual Global Business Intelligence Summit will provide you with the latest industry intelligence on the areas that matter most, including: The Drug Pipeline, Emerging Markets, Integration of Intelligence Functions along with exclusive tips on how to overcome the current economic downturn, The conference will also look in-depth at Competitive Intelligence, tackling issues such as the Ethics of CI, Developing a CI Culture plus primary research advice.

This event guarantees insightful conclusions and takeaway messages for the senior-level pharma audience it will attract. Here is a brief overview of what it the Summit will examine

  • Strategic Overview of Intelligence in 2009 and beyond: Strategies and tactics to ensure how you can safeguard your company from the economic climate, How you can prepare yourself for the impact of US elections on the industry plus a look at payor models all over the world
  • Competitive Intelligence: Understand how the industry is navigating the ethics of CI, learn who is building and integrating a CI function throughout it's business and what they hope to achieve through this and analyse the latest techniques in primary research for today and the future
  • Emerging Markets: Examine what is truly happening in the key emerging markets and what established can learn from them and how we can avoid the minefield of expanding into them
  • Marketing Intelligence: Analyze what your customers want from you! Hear from Forecasters and other pharma functions about how to help them understand and deliver smarter decisions faster!
  • Cross Functional Excellence: Unite data analyses from marketing research, sales analytics, marketing analytics, competitive intelligence, forecasting to drive big picture business decisions
  • IT, Data & Analytics: Discover the best ways to manage primary and secondary vendors and discover the answer to a critical questions: Centralise or De-Centralise Intelligence

For further information and registration, please visit:
http://www.eyeforpharma.com/gbi/

About eyeforpharma
eyeforpharma is a leading global source of information for the pharmaceutical industry. Our reputation has been built on quality, in-depth conferences that have distinguished themselves from competitors by the depth and breadth of research we put into each conference to ensure it is covering the hottest and most pertinent issues of the industry. Months are spent talking directly to senior executives in the industry, as well as relevant consultants and journalists and well respected solutions providers. For more information, please visit www.eyeforpharma.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...